- Published in
- Nature Medicine
- Authors of report
- Brian G. Rash, Kevin N. Ramdas, Anthony A. Oliva Jr.
- Date of report
Summary of the Main Points/Findings
Background and Objective:
This randomized, double-blind, placebo-controlled, parallel-group phase 2a clinical trial aimed to assess the safety and efficacy of laromestrocel, a bone-marrow-derived allogeneic mesenchymal stem-cell therapy, in slowing the progression of Alzheimer’s disease (AD). Given the limited treatment options for AD, the study sought to explore novel therapeutic avenues.
Methods and Findings:
Participants with mild to moderate AD were randomized to receive either laromestrocel or a placebo. The primary outcomes measured included cognitive decline rates and biomarkers of neuroinflammation. The results indicated that laromestrocel was well-tolerated, with some evidence suggesting a slower rate of cognitive decline and reduced neuroinflammation markers in the treatment group compared to placebo.
Conclusion:
The findings suggest that laromestrocel may offer a potential therapeutic benefit in slowing the progression of Alzheimer’s disease. Further large-scale studies are warranted to confirm these results and establish long-term safety profiles.
This is a summary of independent research published elsewhere. It is not a report of Beike treatment outcomes.
